Background illustration for clinical trials search

Weight Loss Clinical Trials

Find clinical trials for weight loss. Search for weight loss clinical trials in different cities and states across the United States.

Filter
FeaturedActive & Responsive

Weight Loss Studies for Adults With a BMI of 27+, Including People Managing Type 2 Diabetes or Sleep Apnea

for
Obesity, Overweight, Diabetes Mellitus, Type 2,
Location: East Greenwich RI, Hampton VA, New Bern NC,

Sex: All

Age: 18+

Recruiting
FeaturedActive & Responsive

The Heartland Study

for
Pregnancy Related, Pregnancy Complications, Birth Defect,
Location: Indianapolis IN, Marshfield WI, Iowa City IA
Sponsor: Heartland Health Research Alliance

Sex: Female

Age: 18+

Code: NCT05492708

Recruiting
Active & Responsive

Testing a Tailored Approach to Long-Term Weight Loss Success

for
Weight Loss, Weight Regain, Obesity & Overweight
Location: Salt Lake City UT
Sponsor: University of Utah

Sex: All

Age: 18 - 65

Code: NCT07577765

Recruiting
Active & Responsive

Individualized Pharmacological Approach to Obesity in Patients With Bipolar Disorder

for
Bipolar I Disorder, Bipolar II Disorder,
Location: Rochester MN
Sponsor: Mayo Clinic

Sex: All

Age: 18 - 65

Code: NCT07213466

Recruiting
Active & Responsive

Fasted vs. Fed State Exercise

for
Obesity, Exercise, Weight Loss
Location: Fort Smith AR
Sponsor: Arkansas Colleges of Health Education

Sex: All

Age: 18 - 59

Code: NCT07487090

Phase 2, Recruiting

Interested in new trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image
Active & Responsive

Effect of Endoscopic Sleeve Gastroplasty in Patients With Obesity and MASH: A Randomized Controlled Trial

for
Obesity, Liver Diseases, Liver Fibrosis, Liver Fat,
Location: Boston MA, Morgantown WV
Sponsor: Pichamol Jirapinyo, MD, MPH

Sex: All

Age: 18+

Code: NCT06138821

Recruiting
Active & Responsive

Exercise Effects on Adipose Tissue Structure and Function

for
Obesity, Metabolic Syndrome, Metabolic Disease,
Location: Ann Arbor MI
Sponsor: University of Michigan

Sex: All

Age: 18 - 40

Code: NCT04812314

Recruiting
Active & Responsive

Metabolic Adaptations to Weight Loss With and Without Exercise

for
Obesity, Metabolic Disease, Metabolic Syndrome,
Location: Ann Arbor MI
Sponsor: University of Michigan

Sex: All

Age: 18 - 40

Code: NCT05806801

Recruiting
Active & Responsive

Randomized Study on Transoral Outlet Reduction and Lifestyle Changes for Weight Regain After Gastric Bypass

for
Weight Regain, Weight Loss
Location: New York NY, Orlando FL, Jacksonville FL, Tampa FL,
Sponsor: Boston Scientific Corporation

Sex: All

Age: 18+

Code: NCT07015424

Recruiting
Active & Responsive

International Weight Control Registry

for
Weight Loss, Overweight, Obesity
Location: Boston MA, Durham NH, West Point NY, Birmingham AL,
Sponsor: Tufts University

Sex: All

Age: 18+

Code: NCT04907396

Recruiting
Active & Responsive

Endoscopic Bariatric Therapies (EBTs): A Retrospective and Prospective Multicenter Registry

for
Obesity, Weight Loss, Gastro Esophageal Reflux,
Location: New York NY
Sponsor: Weill Medical College of Cornell University

Sex: All

Age: 18 - 70+

Code: NCT04494048

Recruiting
Active & Responsive

Effectiveness Study of a Lifestyle Intervention Versus Metformin in Mothers With Recent Gestational Diabetes

for
Weight Loss, Gestational Diabetes Mellitus in Pregnancy,
Location: Washington D.C. DC
Sponsor: George Washington University

Sex: Female

Age: 18 - 45

Code: NCT06948825

Phase 2, Recruiting
Active & Responsive

Unintentional Weight Loss and Cancer: A Prospective Trial of Patient-centered Weight Tracking Combined With GRAIL Galleri Testing to Improve Early Detection

for
Unintended Weight Loss
Location: Cleveland OH
Sponsor: Case Comprehensive Cancer Center

Sex: All

Age: 40 - 70+

Code: NCT05481697

Recruiting
Active & Responsive

Georgia CEAL RESTORES Family Diabetes Study

for
Weight Reduction, Prediabetes
Location: Atlanta GA
Sponsor: Morehouse School of Medicine

Sex: All

Age: 12+

Code: NCT07808723

Recruiting
Active & Responsive

Experimental Approach to Test Predictions of Body Weight Regulation Models

for
Obesity, Underweight
Location: Baton Rouge LA
Sponsor: Pennington Biomedical Research Center

Sex: All

Age: 18 - 40

Code: NCT06309576

Recruiting
Active & Responsive

RemI for Post-Bariatric Surgery Weight Regain

for
Obesity, Bariatric Surgery Candidate
Location: Philadelphia PA, Chicago IL
Sponsor: Temple University

Sex: All

Age: 18 - 70

Code: NCT06292936

Recruiting
Active & Responsive

The Effects of Bariatric Surgeries on Glucose Metabolism

for
Post Bariatric Surgery, Gastric Bypass, Sleeve Gastrectomy,
Location: San Antonio TX
Sponsor: The University of Texas Health Science Center at San Antonio

Sex: All

Age: 18 - 65

Code: NCT02823665

Early Phase 1, Recruiting
Active & Responsive

Effect of Weight Loss on Intermuscular Adipose Tissue (IMAT) Signaling

for
Obesity, Insulin Sensitivity, Muscle Weakness, Adiposity,
Location: Aurora CO
Sponsor: University of Colorado, Denver

Sex: All

Age: 18 - 70

Code: NCT06129110

Recruiting
Active & Responsive

Cognitive Strategies for Weight Loss

for
Obesity
Location: Providence RI
Sponsor: The Miriam Hospital

Sex: All

Age: 18 - 70

Code: NCT05799846

Recruiting
Active & Responsive

A Self-compassion Focused Intervention for Internalized Weight Bias and Weight Loss

for
Overweight and Obesity
Location: Greenville NC
Sponsor: East Carolina University

Sex: All

Age: 18+

Code: NCT05987306

Recruiting

What weight loss treatments are being studied

GLP-1 and combination medicines. The medicines that reshaped the field mimic a gut hormone called GLP-1 that signals fullness and slows digestion. Semaglutide (Wegovy) was approved for weight management in June 2021 and produced about 15 percent weight loss in its main trial; tirzepatide (Zepbound), which acts on GLP-1 and a second hormone, GIP, was approved in November 2023 and produced up to about 21 percent. Trials now test medicines that add a third hormone signal or pair a GLP-1 with amylin, another appetite hormone, aiming for larger and more durable weight loss; the CagriSema combination, for example, is under FDA review after Phase 3 trials, and its confirmatory studies are still enrolling.

Pills. For years every effective option was an injection. In December 2025 the FDA approved a semaglutide tablet (Wegovy pill), and on April 1, 2026 it approved orforglipron (Foundayo), the first GLP-1 pill that can be taken at any time without food or water restrictions, after trials in which people lost about 11 to 12 percent of body weight over 72 weeks. Current orforglipron trials test the pill in groups the approval studies did not cover, including adolescents and people who have already lost weight on an injection and want to maintain it.

Weight loss surgery. Bariatric surgery remains the most effective and longest lasting treatment for severe obesity, with roughly a quarter of a million operations performed in the US each year, most of them sleeve gastrectomy or gastric bypass. Trials study how surgery changes metabolism, how to prevent weight regain afterward, and how surgery compares with or combines with the new medicines.

Devices and endoscopic procedures. Between medicine and surgery sit procedures done through the mouth with no incision: endoscopic sleeve gastroplasty, which stitches the stomach smaller from the inside and was authorized by the FDA in 2022; intragastric balloons, which sit in the stomach for six months; and revision procedures for people who regained weight after bypass. Trials compare newer devices against established ones and measure how long results hold.

GLP-1 medication trials

Weight loss surgery and device trials

Who can participate in weight loss treatment trials

Do participants get paid?

How to enroll in a weight loss clinical trial